Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome - PubMed (original) (raw)
Review
. 2015 Dec;19(23):4654-63.
Affiliations
- PMID: 26698265
Free article
Review
Clinical applications of sodium oxybate (GHB): from narcolepsy to alcohol withdrawal syndrome
F P Busardò et al. Eur Rev Med Pharmacol Sci. 2015 Dec.
Free article
Abstract
Gamma-hydroxybutyrate (GHB) is a short chain fatty acid endogenously produced within the central nervous system (CNS) and acts as a precursor and metabolite of the inhibitory neurotransmitter γ-aminobutyric acid (GABA). Although, it is an illegal recreational drug of abuse, its sodium salt (sodium oxybate) has been utilized as a medication for a number of medical conditions. The first aim of this review was to focus on current applications of sodium oxybate for the treatment of narcolepsy, with a particular emphasis on the key symptoms of this disorder: cataplexy and excessive daytime sleepiness (EDS). Secondly, the effectiveness of sodium oxybate therapy for the treatment of alcohol withdrawal syndrome (AWS) and the maintenance of alcohol abstinence has been assessed. Nowadays, sodium oxybate is the first-line treatment for narcolepsy and it is highly effective in meliorating sleep architecture, decreasing EDS and the frequency of cataplexy attacks in narcoleptic patients. Sodium oxybate currently finds also application in the treatment of AWS and the maintenance of alcohol abstinence in alcoholics. Most of the studies evaluating the efficacy of GHB in the treatment of AWS use a dosage of 50 mg/kg divided in three or four administrations per day. Human studies showed that GHB (dose of 50 mg/kg, divided in three administrations per day) is capable to increase the number of abstinent days, reduce alcohol craving and decrease the number of drinks per day. However, there is limited randomized evidence and, thus, GHB cannot be reliably compared to clomethiazole or benzodiazepines. Some randomized data suggest that GHB is better than naltrexone and disulfiram regarding abstinence maintenance and prevention of craving in the medium term i.e. 3-12 months. It is recommended that GHB should be used only under strict medical supervision, since concerns about the abuse/misuse of the drug and the addiction potential have been arisen.
Similar articles
- Sodium Oxybate Therapy for Alcohol Withdrawal Syndrome and Keeping of Alcohol Abstinence.
Mannucci C, Pichini S, Spagnolo EV, Calapai F, Gangemi S, Navarra M, Calapai G. Mannucci C, et al. Curr Drug Metab. 2018;19(13):1056-1064. doi: 10.2174/1389200219666171207122227. Curr Drug Metab. 2018. PMID: 29219048 Review. - Gamma-hydroxybutyrate (GHB) for treatment of alcohol withdrawal and prevention of relapses.
Leone MA, Vigna-Taglianti F, Avanzi G, Brambilla R, Faggiano F. Leone MA, et al. Cochrane Database Syst Rev. 2010 Feb 17;(2):CD006266. doi: 10.1002/14651858.CD006266.pub2. Cochrane Database Syst Rev. 2010. PMID: 20166080 Review. - The abrupt cessation of therapeutically administered sodium oxybate (GHB) does not cause withdrawal symptoms.
[No authors listed] [No authors listed] J Toxicol Clin Toxicol. 2003;41(2):131-5. doi: 10.1081/clt-120019128. J Toxicol Clin Toxicol. 2003. PMID: 12733850 Clinical Trial. - Sodium oxybate: a review of its use in the management of narcolepsy.
Robinson DM, Keating GM. Robinson DM, et al. CNS Drugs. 2007;21(4):337-54. doi: 10.2165/00023210-200721040-00007. CNS Drugs. 2007. PMID: 17381187 Review. - Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials.
Boscolo-Berto R, Viel G, Montagnese S, Raduazzo DI, Ferrara SD, Dauvilliers Y. Boscolo-Berto R, et al. Sleep Med Rev. 2012 Oct;16(5):431-43. doi: 10.1016/j.smrv.2011.09.001. Epub 2011 Nov 4. Sleep Med Rev. 2012. PMID: 22055895 Review.
Cited by
- Individual differences in GHB consumption in a new voluntary GHB self-administration model in outbred rats.
Wolf CJH, Spoelder M, Beurmanjer H, Bulthuis R, Schellekens AFA, Homberg JR. Wolf CJH, et al. Psychopharmacology (Berl). 2024 Mar;241(3):613-625. doi: 10.1007/s00213-024-06537-5. Epub 2024 Feb 9. Psychopharmacology (Berl). 2024. PMID: 38334790 Free PMC article. - Alcohol Use Disorder and Associated Factors Among Elderly in Ethiopia.
Wolde A. Wolde A. Subst Abuse. 2023 Mar 1;17:11782218231158031. doi: 10.1177/11782218231158031. eCollection 2023. Subst Abuse. 2023. PMID: 36875744 Free PMC article. - A Comparison Study of Impulsiveness, Cognitive Function, and P300 Components Between Gamma-Hydroxybutyrate and Heroin-Addicted Patients: Preliminary Findings.
Zeng T, Li S, Wu L, Feng Z, Fan X, Yuan J, Wang X, Meng J, Ma H, Zeng G, Kang C, Yang J. Zeng T, et al. Front Hum Neurosci. 2022 Apr 20;16:835922. doi: 10.3389/fnhum.2022.835922. eCollection 2022. Front Hum Neurosci. 2022. PMID: 35529779 Free PMC article. - Current Insights on the Impact of Gamma-Hydroxybutyrate (GHB) Abuse.
Tay E, Lo WKW, Murnion B. Tay E, et al. Subst Abuse Rehabil. 2022 Feb 9;13:13-23. doi: 10.2147/SAR.S315720. eCollection 2022. Subst Abuse Rehabil. 2022. PMID: 35173515 Free PMC article. Review. - Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder.
Burnette EM, Nieto SJ, Grodin EN, Meredith LR, Hurley B, Miotto K, Gillis AJ, Ray LA. Burnette EM, et al. Drugs. 2022 Feb;82(3):251-274. doi: 10.1007/s40265-021-01670-3. Epub 2022 Feb 8. Drugs. 2022. PMID: 35133639 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical